101258-12-2

Basic information

• Product Name: 3-(1-Methyl-1H-tetrazol-5-yl)aniline
• Synonyms: 1-Methyl-5-(3-aminophenyl)tetrazole;3-(1-methyl-1H-tetrazol-5-yl)Benzenamine
• CAS NO: 101258-12-2
• Molecular Formula: C₈H₉N₅
• Molecular Weight: 175.19
• Mol File: 101258-12-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 410.442 °C at 760 mmHg
• Flash Point: 202.028 °C
• Appearance: /
• Density: 1.4 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.715
• CAS DataBase Reference: 3-(1-Methyl-1H-tetrazol-5-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(1-Methyl-1H-tetrazol-5-yl)aniline(101258-12-2)
• EPA Substance Registry System: 3-(1-Methyl-1H-tetrazol-5-yl)aniline(101258-12-2)

Safety Data

• Hazardous Substances Data: 101258-12-2(Hazardous Substances Data)

Usage

General Description

3-(1-Methyl-1H-tetrazol-5-yl)aniline, also known as MTA, is a chemical compound with the molecular formula C8H9N5. It is a member of the tetrazole family of compounds and is commonly used as a building block in the synthesis of pharmaceutical drugs and agrochemicals. MTA is a white to off-white solid that is soluble in organic solvents and is relatively stable under normal conditions. It has been utilized in the development of drugs for conditions such as hypertension, diabetes, and cancer, and it is also used as a reagent in chemical research and analysis. However, MTA is not without its risks, as it is classified as a hazardous substance and should be handled with care in a laboratory setting.

InChI:InChI=1/C8H9N5/c1-13-8(10-11-12-13)6-3-2-4-7(9)5-6/h2-5H,9H2,1H3

Upstream product

• 20743-50-4 1-methyl-5-phenyltetrazole 
• 69746-32-3 1-methyl-5-(3-nitrophenyl)-tetrazole 

Downstream Products

• 1251526-16-5 C₂HF₃O₂*C₂₆H₃₀ClN₇O₂ 
• 382637-78-7 [3-(1-methyl-1H-tetrazol-5-yl)-phenyl]-carbamic acid phenyl ester 

Relevant articles and documents

Discovery of mercaptopropanamide-substituted aryl tetrazoles as new broad-spectrum metallo-β-lactamase inhibitors

β-Lactam antibiotic resistance mediated by metallo-β-lactamases (MBL) has threatened global public health. There are currently no available inhibitors of MBLs for clinical use. We previously reported the ruthenium-catalyzed meta-selective C-H nitration synthesis method, leading to some meta-mercaptopropanamide substituted aryl tetrazoles as new potent MBL inhibitors. Here, we described the structure-activity relationship of meta- and ortho-mercaptopropanamide substituted aryl tetrazoles with clinically relevant MBLs. The resulting most potent compound 13a showed IC50 values of 0.044 μM, 0.396 μM and 0.71 μM against VIM-2, NDM-1 and IMP-1 MBL, respectively. Crystallographic analysis revealed that 13a chelated to active site zinc ions via the thiol group and interacted with the catalytically important residues Asn233 and Tyr67, providing further structural information for the development of thiol based MBL inhibitors. This journal is

SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of CCR3 of formula (Ia) and (Ib): (I) or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5', R6, a, b

N-substituted heterocyclic amines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.